Редактирование: STK11

Serine/threonine-protein kinase STK11 precursor (EC 2.7.11.1) (Liver kinase B1) (LKB1) (hLKB1) (Renal carcinoma antigen NY-REN-19) [LKB1] [PJS]

==Publications==

{{medline-entry
|title=A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/28407996
|abstract=The National Comprehensive Cancer Network recommends that women who carry gene variants that confer substantial risk for breast cancer consider risk-reduction strategies, that is, enhanced surveillance (breast magnetic resonance imaging and mammography) or prophylactic surgery. Pathogenic variants can be detected in women with a family history of breast or ovarian cancer syndromes by multigene panel testing. To investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy. We estimated effectiveness and lifetime costs from a payer perspective for two strategies in two hypothetical cohorts of women (40-year-old and 50-year-old cohorts) who meet the National Comprehensive Cancer Network-defined family history criteria for multigene testing. The two strategies were the usual test strategy for variants in [[BRCA1]] and [[BRCA2]] and the seven-gene test strategy for variants in [[BRCA1]], [[BRCA2]], [[TP53]], [[PTEN]], [[CDH1]], [[STK11]], and [[PALB2]]. Women found to have a pathogenic variant were assumed to undergo either prophylactic surgery or enhanced surveillance. The incremental cost-effectiveness ratio for the seven-gene test strategy compared with the [[BRCA1]]/2 test strategy was $42,067 per life-year gained or $69,920 per quality-adjusted life-year gained for the 50-year-old cohort and $23,734 per life-year gained or $48,328 per quality-adjusted life-year gained for the 40-year-old cohort. In probabilistic sensitivity analysis, the seven-gene test strategy cost less than $100,000 per life-year gained in 95.7% of the trials for the 50-year-old cohort. Testing seven breast cancer-associated genes, followed by risk-reduction management, could cost-effectively improve life expectancy for women at risk of hereditary breast cancer.
|mesh-terms=* Adult
* Age Factors
* Aged
* Aged, 80 and over
* Biomarkers, Tumor
* Breast Neoplasms
* Cost-Benefit Analysis
* Decision Support Techniques
* Early Detection of Cancer
* Female
* Gene Expression Profiling
* Genetic Predisposition to Disease
* Genetic Testing
* Health Care Costs
* Heredity
* Humans
* Life Expectancy
* Magnetic Resonance Imaging
* Mammography
* Mastectomy
* Middle Aged
* Models, Economic
* Patient Selection
* Phenotype
* Predictive Value of Tests
* Prognosis
* Quality-Adjusted Life Years
* Risk Assessment
* Risk Factors
* Watchful Waiting
|keywords=* BRCA
* breast cancer
* cost-effectiveness
* multigene panel testing
|full-text-url=https://sci-hub.do/10.1016/j.jval.2017.01.006
}}